Skip to main content
Erschienen in: Annals of Surgical Oncology 7/2019

04.04.2019 | Colorectal Cancer

Sidedness of Colorectal Cancer Impacts Risk of Second Primary Gastrointestinal Malignancy

verfasst von: Kristy K. Broman, MD, MPH, Christina E. Bailey, MD, MSCI, Alexander A. Parikh, MD, MPH

Erschienen in: Annals of Surgical Oncology | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Introduction

A history of colorectal cancer (CRC) increases the risk of subsequent gastrointestinal (GI) cancer. Cancers of the right colon, left colon, and rectum differ according to molecular profiles, responses to treatment, and outcomes.

Objective

The purpose of this study was to determine if CRC location is associated with differential risk for secondary primary GI malignancy.

Methods

A retrospective cohort of adults with CRC was compiled using the Surveillance, Epidemiology, and End Results database (1973–2015). Standardized incidence ratios (SIRs) for second primary GI malignancies were compared based on location of the index CRC (right colon, left colon, or rectum).

Results

The cohort included 281,413 adults with CRC (30.3% right, 35.3% left, 34.3% rectum). With a median 4.9-year follow-up, 12,064 (4.3%) patients developed a second primary GI malignancy (64% CRC, 36% non-CRC). Those with CRC at any location had higher than expected incidences of small intestine, bile duct, and other CRCs, and lower incidences of liver and gallbladder cancer. The SIR for small intestinal cancer was higher after right colon cancer than after left colon or rectal cancer. The esophageal cancer SIR was higher after left colon cancer. Pancreas cancer was higher than expected for right colon cancer, but lower for left colon and rectal cancer.

Conclusion

The location of CRC leads to differences in the incidence and location of second primary GI malignancies and may be related to similarities in the associated carcinogenesis and molecular pathways or response to treatment. CRC location not only impacts treatment response and outcomes, but should also be considered during subsequent surveillance.
Literatur
1.
Zurück zum Zitat Morton LM, Savage SA, Bhatia S. Multiple primary cancers. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 2017. Morton LM, Savage SA, Bhatia S. Multiple primary cancers. In: Schottenfeld D, Fraumeni JF, editors. Cancer epidemiology and prevention. New York: Oxford University Press; 2017.
2.
Zurück zum Zitat Allemani C, Weir HK, Carreira H, et al. The CONCORD working group. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385(9972):977–1010. Allemani C, Weir HK, Carreira H, et al. The CONCORD working group. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015;385(9972):977–1010.
3.
Zurück zum Zitat Curtis RE, Freedman DM, Ron E, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH Publication no. 05-5302. Bethesda: National Cancer Institute. Curtis RE, Freedman DM, Ron E, et al., editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH Publication no. 05-5302. Bethesda: National Cancer Institute.
6.
Zurück zum Zitat 6Bufill J. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–788.CrossRefPubMed 6Bufill J. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779–788.CrossRefPubMed
7.
Zurück zum Zitat Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol. 2001;13:63–69.CrossRefPubMed Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol. 2001;13:63–69.CrossRefPubMed
8.
Zurück zum Zitat Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer. JAMA Oncology. 2017;3(2):211–219.CrossRefPubMed Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer. JAMA Oncology. 2017;3(2):211–219.CrossRefPubMed
9.
Zurück zum Zitat Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumor location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;10:87–98.CrossRef Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V. The relevance of primary tumor location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;10:87–98.CrossRef
10.
Zurück zum Zitat Arnold D, Lueza B, Douillard J-Y, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–1729.CrossRefPubMedPubMedCentral Arnold D, Lueza B, Douillard J-Y, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28:1713–1729.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance) [abstract no. 3504]. 2016 ASCO annual meeting; 3–7 June 2016: Chicago, IL. Venook AP, Niedzwiecki D, Innocenti F, et al. Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB/SWOG 80405 (Alliance) [abstract no. 3504]. 2016 ASCO annual meeting; 3–7 June 2016: Chicago, IL.
12.
Zurück zum Zitat Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664–3672.CrossRefPubMedPubMedCentral Sinicrope FA, Mahoney MR, Smyrk TC, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664–3672.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Ulivi P, Scarpi E, Chiadini E, et al. Right- vs left-sided metastatic colorectal cancer: differences in tumor biology and bevacizumab efficacy. Int J Mol Sci. 2017;18(6):1240.CrossRefPubMedCentral Ulivi P, Scarpi E, Chiadini E, et al. Right- vs left-sided metastatic colorectal cancer: differences in tumor biology and bevacizumab efficacy. Int J Mol Sci. 2017;18(6):1240.CrossRefPubMedCentral
14.
Zurück zum Zitat Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170.CrossRefPubMed Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170.CrossRefPubMed
15.
Zurück zum Zitat Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2017 Sub (1973–2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission (www.seer.cancer.gov). Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: Incidence—SEER 9 Regs Research Data, Nov 2017 Sub (1973–2015) <Katrina/Rita Population Adjustment>—Linked To County Attributes—Total U.S., 1969–2016 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2018, based on the November 2017 submission (www.​seer.​cancer.​gov).
18.
Zurück zum Zitat Guan X, Jin Y, Chen Y, et al. The incidence characteristics of secondary primary malignancy after diagnosis of primary colon and rectal cancer: a population based study. PLoS One. 2015;10(11):E0143067.CrossRefPubMedPubMedCentral Guan X, Jin Y, Chen Y, et al. The incidence characteristics of secondary primary malignancy after diagnosis of primary colon and rectal cancer: a population based study. PLoS One. 2015;10(11):E0143067.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kauffman RM, Wang L, Phillips S, Idrees K, Merchant N, Parikh A. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Ann Surg Oncol. 2014;21:3422–3428.CrossRef Kauffman RM, Wang L, Phillips S, Idrees K, Merchant N, Parikh A. Incidence of additional primary malignancies in patients with pancreatic and gastrointestinal neuroendocrine tumors. Ann Surg Oncol. 2014;21:3422–3428.CrossRef
21.
Zurück zum Zitat Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biopsy: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw. 2017;15(3): 411–419.CrossRef Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biopsy: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw. 2017;15(3): 411–419.CrossRef
22.
Zurück zum Zitat Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21(21):6470–6478.CrossRefPubMedPubMedCentral Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right-sided and left-sided colon cancers. World J Gastroenterol. 2015;21(21):6470–6478.CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat McCredie M, Macfarlane GJ, Bell J, Coates M. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972–1991. Cancer Epidemiol Biomarker Prev. 1997. 6(3):155–160. McCredie M, Macfarlane GJ, Bell J, Coates M. Second primary cancers after cancers of the colon and rectum in New South Wales, Australia, 1972–1991. Cancer Epidemiol Biomarker Prev. 1997. 6(3):155–160.
24.
Zurück zum Zitat Neugut AI, Santos J. The association between cancers of the small and large bowel. Cancer Epidemiol Biomarker Prev. 1993;2(6):551–553. Neugut AI, Santos J. The association between cancers of the small and large bowel. Cancer Epidemiol Biomarker Prev. 1993;2(6):551–553.
25.
Zurück zum Zitat Bojesen RD, Riis LB, Hogdall E, Neilsen OH, Jess T. Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study. Clin Gastroenterol Hepatol. 2017;15(12):1900–1907.CrossRefPubMed Bojesen RD, Riis LB, Hogdall E, Neilsen OH, Jess T. Inflammatory bowel disease and small bowel cancer risk, clinical characteristics, and histopathology: a population-based study. Clin Gastroenterol Hepatol. 2017;15(12):1900–1907.CrossRefPubMed
26.
Zurück zum Zitat Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol. 2005;100:703–710.CrossRefPubMed Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol. 2005;100:703–710.CrossRefPubMed
27.
Zurück zum Zitat Reddy BS, Wynder EL. Large-bowel carcinogenesis: fecal constituents of populations with diverse incidence rates of colon cancer. J Natl Cancer Inst. 1973;50:1437–1442.CrossRefPubMed Reddy BS, Wynder EL. Large-bowel carcinogenesis: fecal constituents of populations with diverse incidence rates of colon cancer. J Natl Cancer Inst. 1973;50:1437–1442.CrossRefPubMed
28.
Zurück zum Zitat Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarker Prev. 1998;7(3):243–251. Neugut AI, Jacobson JS, Suh S, Mukherjee R, Arber N. The epidemiology of cancer of the small bowel. Cancer Epidemiol Biomarker Prev. 1998;7(3):243–251.
29.
Zurück zum Zitat Woodford-Richens AK, Rowan AJ, Gorman R, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microstallite instability pathway. Proc Natl Acad Sci U S A. 2001;98(17):9719–9723.CrossRefPubMedPubMedCentral Woodford-Richens AK, Rowan AJ, Gorman R, et al. SMAD4 mutations in colorectal cancer probably occur before chromosomal instability, but after divergence of the microstallite instability pathway. Proc Natl Acad Sci U S A. 2001;98(17):9719–9723.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Solovaara R, Roth S, Loukola A, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut. 2002;51:56–59.CrossRef Solovaara R, Roth S, Loukola A, et al. Frequent loss of SMAD4/DPC4 protein in colorectal cancers. Gut. 2002;51:56–59.CrossRef
31.
Zurück zum Zitat Howden CW, Hornung CA. A systematic review of the association between Barrett’s esophagus and colon neoplasms. Am J Gastroenterol. 1995;90(10):1814–1819.PubMed Howden CW, Hornung CA. A systematic review of the association between Barrett’s esophagus and colon neoplasms. Am J Gastroenterol. 1995;90(10):1814–1819.PubMed
32.
Zurück zum Zitat Siersema PD, Yu S, Sahbaie P. Colorectal neoplasia in veterans is associated with Barrett’s esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc. 2006;63(40):581–586.CrossRefPubMed Siersema PD, Yu S, Sahbaie P. Colorectal neoplasia in veterans is associated with Barrett’s esophagus but not with proton-pump inhibitor or aspirin/NSAID use. Gastrointest Endosc. 2006;63(40):581–586.CrossRefPubMed
33.
Zurück zum Zitat Jorgensen T, Rafaelsen S. Gallstones and colorectal cancer—there is a relationship, but it is hardly due to cholecystectomy. Dis Colon Rectum. 1992;35(1):24CrossRefPubMed Jorgensen T, Rafaelsen S. Gallstones and colorectal cancer—there is a relationship, but it is hardly due to cholecystectomy. Dis Colon Rectum. 1992;35(1):24CrossRefPubMed
34.
Zurück zum Zitat Shabanzadeh DM, Sorensen LT, Jorgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study. Gastroenterology. 2017;152(8):1965–1974.CrossRefPubMed Shabanzadeh DM, Sorensen LT, Jorgensen T. A prediction rule for risk stratification of incidentally discovered gallstones: results from a large cohort study. Gastroenterology. 2017;152(8):1965–1974.CrossRefPubMed
Metadaten
Titel
Sidedness of Colorectal Cancer Impacts Risk of Second Primary Gastrointestinal Malignancy
verfasst von
Kristy K. Broman, MD, MPH
Christina E. Bailey, MD, MSCI
Alexander A. Parikh, MD, MPH
Publikationsdatum
04.04.2019
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 7/2019
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07326-7

Weitere Artikel der Ausgabe 7/2019

Annals of Surgical Oncology 7/2019 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.